A-myb, a conserved member of the Myb proto-oncogene family, encodes a sequence-speci®c DNA binding protein (A-Myb) that binds to and transactivates promoters containing myb-binding sites. Previous work has suggested that the C-terminus of A-Myb functions as a regulatory domain, however, the physiological signals that control the activity of A-Myb have not yet been identi®ed. The presence of potential phosphorylation sites for cyclin-dependent kinases in the C-terminus of A-Myb has prompted us to examine the possibility that the function of A-Myb is controlled by the cell cycle. We here show that the transactivation potential of A-Myb is repressed by the C-terminal domain and that phosphorylation of A-Myb, induced by cyclins A and E, relieves this inhibitory eect. Our work provides the ®rst evidence that the function of A-Myb is regulated by the cell cycle machinery and that the carboxy-terminal domain of A-Myb acts as a cell cycle sensor. In addition, we show that A-myb mRNA expression is also cell cycle regulated and attains maximal levels during the late G 1 -and early S-phase. Thus, A-Myb appears to be controlled by two dierent mechanisms resulting in maximal A-Myb activity during the G 1 /S-transition and the S-phase of the cell cycle.
Introduction
During recent years the cyclins and their catalytic partners, the cyclin-dependent kinases (CDKs), have been identi®ed as key molecules regulating the eukaryotic cell cycle (for review see: MassagueÂ and Roberts, 1995; and references therein) . It is now generally accepted that speci®c cyclin/CDK complexes appear sequentially during the cell cycle and control cell cycle progression by phosphorylating speci®c target proteins. In particular, complexes of cyclin D1 and CDK4 and CDK6 have been shown to play a key role at the restriction point in the G 1 phase of the cell cycle, whereas cyclin E/CDK2 complexes are most critical for the transition from the G 1 -to the S-phase and cyclin A/CDK2 complexes are required during the S-phase (Girard et al., 1991; Tsai et al., 1991; Dulic et al., 1992; Elledge et al., 1992; Ko et al., 1992; Pagano et al., 1992; Rosenblatt et al., 1992; Ohtsubo and Roberts, 1993; Sherr, 1993; Draetta, 1994; Knoblich et al., 1994) . Although certain cyclin-CDK target proteins have been studied in great detail, such as the retinoblastoma protein (for review see: Weinberg, 1995) , many of the targets, particularly those of cyclins E and A, likely remain to be identi®ed.
A-myb is a member of the myb proto-oncogene family conserved in most or all vertebrates (Nomura et al., 1988; Bouwmeester et al., 1992; Sleeman, 1993; Foos et al., 1994; Trauth et al., 1994) . Like other myb family members, the A-myb protein (A-Myb) is a sequence speci®c DNA binding protein which binds to and transactivates promoters containing Myb binding sites (Trauth et al., 1994; Foos et al., 1994; Golay et al., 1994; Takahashi et al., 1995) . Whereas the founding member of the myb family c-myb, seems to be essential only for hematopoietic cells (Mucenski et al., 1991; Graf, 1992) , A-myb is expressed in certain hematopoietic as well as non-hematopoietic cell types (Trauth et al., 1994; Mettus et al., 1994; Sitzmann et al., 1995; Latham et al., 1996) . Because of their functional and structural similarity and their divergent expression patterns (Sitzmann et al., 1995) it has been suggested that c-Myb and A-Myb are functional homologs that perform similar roles in dierent cell types. This notion has been strongly supported by the recent observation that spermatogenesis is defective in mice lacking A-myb (Toscani et al., 1997) .
Recently, it has been observed that the C-terminus of A-Myb inhibits the transactivation potential of the protein, raising the possibility that this part of A-Myb has a regulatory role (Takahashi et al., 1995) . Here, we have investigated the regulation of the A-Myb activity by the C-terminal domain in more detail. We show that the transactivation potential of A-Myb is repressed by the C-terminus of the protein and that phosphorylation of A-Myb, induced by cyclins A and E, relieves this inhibitory eect. In addition, we show that A-myb mRNA expression is also regulated during the cell cycle. Taken together, our data suggest that AMyb is controlled by several mechanisms that direct its activity to the G 1 /S-transition and the onset of the Sphase.
myb-dependent reporter gene p3xATk-Luc (which contains three copies of a myb binding site cloned upstream of the HSV thymindine kinase promoter) with expression vectors for full-length or C-terminally deleted A-Myb showed that C-terminal truncation substantially increased the activity of the protein (Figure 1b) . This stimulation was not due to increased expression of the truncated protein ( Figure  1c ). These results show that transactivation by mouse A-Myb is repressed by the C-terminus of the protein and raise the possibility that this part of A-Myb acts as a regulatory domain.
Cyclin dependent modulation of the transactivation potential of A-Myb
The C-terminus of A-Myb contains a number of potential phosphorylation sites for cyclin-dependent kinases, raising the possibility that A-Myb activity is controlled by cell cycle dependent phosphorylation of the C-terminus. To explore this possibility, we examined as a ®rst step the eect of ectopic expression of cyclins A, D1 and E on the transactivation potential of A-Myb. As shown in Figure 2a , the co-expression of full-length A-Myb and cyclins A and E, but not cyclin D1, resulted in an increase of the transactivation potential of A-Myb. This increase was also observed when other reporter genes were used to monitor the transactivation potential of A-Myb (Figure 3 , and data not shown), suggesting that it was a general eect. Transactivation by c-Myb was not increased by cyclin A (Figure 2b ) or cyclin E (data not shown), indicating that the cyclin dependent increase of A-Myb activity was speci®c. To investigate whether the cyclin dependent increase of A-Myb activity was mediated by the C-terminal domain of A-Myb, we studied the eect of cyclin A on transactivation by the C-terminal deletion mutant A-Myb-DBamHI. Interestingly, the activity of the truncated protein was not increased further by cyclin A or cyclin E (Figure 2c) , consistent with the idea that cyclin A and cyclin E counteract the inhibitory eect of the C-terminal domain.
The natural kinase partner for cyclin A and E during the G 1 /S-transition and during the S-phase has been identi®ed as CDK2 (reviewed in: Sherr, 1993; Draetta, 1994) . To investigate whether the endogenous CDK2 present in the transfected cells is involved in the cyclin A or E dependent stimulation of A-Myb activity, we co-expressed A-Myb and cyclins A or E with increasing amounts of a dominant-negative mutant of CDK2 (van den Heuvel and Harlow, 1993) . As shown in Figure 2d , the dominant-negative form of CDK2 suppressed the stimulation of A-Myb by cyclin A and E, presumably by titrating out the endogenous CDK2. Transactivation by A-Myb in the absence of ectopically expressed cyclins was not signi®cantly inhibited by the dominant-negative CDK2, suggesting that a basal level of transactivation by A-Myb is constitutive. Additional control experiments showed that transactivation by cMyb or C-terminally truncated A-Myb was not aected by dominant-negative CDK2 (Figure 2e and f).
Cyclin-dependent regulation of A-Myb activity does not require the A-Myb DNA-binding domain To con®rm our observation of a cyclin-dependent increase of the activity of A-Myb by using a dierent assay system for monitoring A-Myb activity, we studied the eect of cyclin A on the activity of Gal4/ A-Myb fusion proteins. As shown in Figure 3 , transactivation of a Gal4-dependent reporter gene by a Gal4/A-Myb fusion protein was stimulated by coexpression with cyclin A. A Gal4/A-Myb hybrid protein lacking the DNA-binding domain of A-Myb was activated similarly by cyclin A. By contrast, the activity of a Gal4/A-Myb fusion protein lacking the Cterminus of A-Myb was not increased further by cyclin A. These results corroborate the observations presented in Figure 2 . Furthermore, they show that the A-Myb 
Cyclin dependent phosphorylation of A-Myb
The eects of cyclins A and E on the activity of AMyb suggested that A-Myb is phosphorylated by complexes of cyclin A-or E and CDK2. Since phosphorylation of a protein can lead to a change of its electrophoretic mobility, A-Myb was co-expressed with cyclins A, D1 or E and examined by SDSpolyacrylamide gel electrophoresis and Western blotting. Figure 4a shows that additional slow-migrating forms of A-Myb were indeed induced by cyclins A and E, but not by cyclin D1 ± instead expression of cyclin D1 resulted in an increase of the amount of A-Myb. By contrast, the mobility of c-Myb or of C-terminally truncated A-Myb was not aected in a cyclindependent manner ( Figure 4a ). Furthermore, the dominant-negative mutant of CDK2 suppressed the appearance of the slow-migrating forms of A-Myb (Figure 4b ), indicating that endogenous CDK2 is involved in generating these slow migrating forms of A-Myb. Taken together, our experiments suggest that the modi®ed forms of A-Myb are caused by cyclin A/ CDK2 and cyclin E-CDK2 complexes.
To examine whether the change of the electrophoretic mobility of A-Myb was due to phosphorylation, we performed in vitro phosphatase-treatment experiments. A-Myb was immunoprecipitated from 35 S-methionine- Figure 5a , the cyclin A-induced slowermigrating forms of A-Myb were converted into the fast-migrating form by the phosphatase treatment, consistent with the notion that the cyclin induced increase in electrophoretic mobility of A-Myb is caused by phosphorylation.
To demonstrate the phosphorylation of A-Myb more directly, A-Myb was co-expressed with cyclins A, D1 and E and labeled in vivo with [ 32 P]orthophosphate. The labeled protein was then analysed by immunoprecipitation and gel electrophoresis. As shown in Figure 5b , cyclins A and E caused a mobility shift of phosphate-labeled A-Myb similar to the shift detected by Western blotting. Furthermore, the amount of phosphate label incorporated into AMyb in the presence of cyclin A or cyclin E was severalfold higher than in its absence, indicating that a net increase of phosphorylation of A-Myb was induced by cyclins A and E. As a control, we showed that Cterminally truncated A-Myb was only weakly labeled by [ 32 P]-orthophosphate and that phosphate incorporation was not increased by cyclins A (Figure 5c ) or E (data not shown). These experiments therefore clearly show that cyclins A and E induce phosphorylation of A-Myb. Furthermore, they show that the C-terminal domain of A-Myb is the major site of phosphorylation.
To investigate whether the cyclin-induced phosphorylation of A-Myb is a direct or indirect eect, we performed in vitro kinase assays using a bacterially expressed GST/A-Myb fusion protein and immunopuri®ed cyclin A-CDK2 kinase. We found that a GST/AMyb fusion protein containing the C-terminus of AMyb was phosphorylated by cyclin A/CDK2 in vitro, whereas the GST-domain alone was not phosphorylated ( Figure 6 ). Moreover, the phosphorylation was much more prominent when the kinase was immunopuri®ed from cells transfected with expression vectors for cyclin A and CDK2 (Figure 6 ). For comparison, Figure 6 also shows the result of an in vitro kinase reaction using a GST-/B-Myb protein, whose direct phosphorylation by cyclin A/CDK2 has been demonstrated before (Ziebold et al., 1997) . Taken together, the results shown in Figure 6 provide strong evidence that the C-terminus of A-Myb is a direct target for cyclin A/CDK2.
Cell cycle dependent expression of mouse A-Myb
The experiments described so far provided evidence that the activity of A-Myb is controlled in a cell cycle manner and, hence, suggested that A-Myb performs a cell cycle dependent function. We were therefore interested to determine whether the expression of Amyb mRNA was also restricted to a certain phase of the cell cycle. Swiss 3T3 ®broblasts were synchronized by serum starvation and labeled with [ 3 H]-thymidine or analysed by Northern blotting at dierent times after re-addition of serum. Figure 7a shows that the cells entered S-phase approximately 14 h after addition of serum. The Northern blot illustrated in Figure 7b shows that A-myb mRNA was expressed as a broad peak between 14 and 24 h after serum stimulation. A similar expression pattern was observed for B-myb and DNA polymerase a mRNAs (Figure 7c and d) , whose expression during the late G 1 -and S-phase of the cell cycle has been demonstrated before Lam et al., 1992) .
Discussion

Cell cycle dependent regulation of A-Myb
The results presented here provide the ®rst evidence that A-Myb, a conserved member of the Myb transcription factor family, is regulated by the cell cycle machinery. Cell cycle dependent regulation of AMyb appears to occur on two levels. Firstly, the expression of A-myb mRNA is cell cycle regulated, showing maximal levels during the late G 1 -and early Sphase. Secondly, our data reveal an additional level of regulation which is mediated by cyclin E and A dependent phosphorylation of the A-Myb protein and modulates its transactivation potential. Work from a number of laboratories has shown that cyclin E/CDK2 and cyclin A/CDK2 complexes play essential roles at the G 1 /S-transition and during the S-phase, respectively (Sherr, 1993; Draetta, 1994) . It therefore appears that both regulatory mechanisms act in concert resulting in a peak of A-Myb activity at the G 1 /S-transition and the onset of the S-phase.
Previous work has shown that the expression of Amyb is restricted to speci®c cell types. During mouse embryonic development A-myb is transiently expressed in certain populations of immature neuronal cells in the central nervous system (Trauth et al., 1994) . In addition A-myb is expressed in spermatogenic progenitor cells and during late stages of B-cell development (Trauth et al., 1994; Sleeman, 1993; Mettus et al., 1994; Golay et al., 1996; Latham et al., 1996) . A-Myb, therefore, seems not to be a general component of the cell cycle machinery but most likely performs a cell cycle-dependent role during the proliferation of certain cell types. This notion has been strongly supported by the observation that spermatogenesis is arrested in mice lacking the Amyb gene (Toscani et al., 1997 ). , for cyclins A, D1 or E (5 mg in a; 1 mg in b) and for a dominantnegative mutant of CKD2 (7 mg) were co-transfected into QT6 cells, as indicated. Control transfections (7) contained equivalent amounts of the appropriate empty vector. To monitor the transfection eciencies the b-galactosidase reporter gene pCMVb (1 mg) was included in each transfection. Twenty-four hours after transfection Myb proteins were analysed by SDS ± PAGE and Western blotting of cell extracts prepared from the transfected cells Because of their functional and structural similarities and their divergent expression patterns (Sitzmann et al., 1995) it has been suggested that c-Myb and A-Myb are functional homologs that perform similar roles in dierent cell types. Interestingly, we failed to detect a cyclin-dependent stimulation of the activity of c-Myb indicating that A-Myb and c-Myb are regulated dierently. The functions of A-Myb and c-Myb may therefore be more dierent than previously suspected.
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The C-terminus of A-Myb is a cell-cycle sensor
Our ®ndings highlight the central role of the Cterminal domain of A-Myb in the cyclin dependent regulation of A-Myb activity. We have shown that the inhibitory function of the C-terminus is counteracted by cyclin/CDK mediated phosphorylation, suggesting that the C-terminus of A-Myb acts as a cell cycle sensor. Although we have not yet mapped individual phosphorylation sites in A-Myb, our results indicate that the C-terminus of the protein is the major site of phosphorylation. This is consistent with most of the potential phosphorylation motifs being clustered in the C-terminal half of the protein.
How does phosphorylation of A-Myb aect its transactivation activity? In principle, our results are compatible with various mechanisms involving phosphorylation dependent intra-or intermolecular interactions. Dash et al. (1996) have recently presented evidence for an intramolecular interaction that regulates the activity of c-Myb and involves a small region, the so called EVES motif, in the c-terminal part of c-Myb and the DNA-binding domain. Although there is some aminoacid sequence conservation between the C-terminal domains of A-Myb and cMyb, the cyclin-dependent stimulation of the activity of A-Myb is, most likely, due to a dierent mechanism. We have shown that the activity of a Gal4/A-Myb fusion protein lacking the A-Myb DNA binding domain is stimulated by cyclin A. This suggests that the cyclin-dependent regulation of A-Myb also operates in the absence of the A-Myb DNA-binding domain and, therefore, appears not to involve a change in the DNA-binding activity of the protein.
Regulation of Myb activity by phosphorylation is not an entirely new concept. LuÈ scher et al. (1990) have previously shown that the DNA-binding activity of cMyb is regulated casein kinase II (CKII) mediated phosphorylation of sequences residing at the aminoterminus of c-Myb. A CKII consensus phosphorylation motif is present at the aminoterminus of A-Myb, raising the possibility that a similar regulatory mechanism also operates on A-Myb. Furthermore, cMyb has been shown to be phosphorylated by MAP kinase at a site located in the C-terminal half of the protein (Aziz et al., 1993 (Aziz et al., , 1995 . This suggests that cMyb is regulated by a signalling pathway acting through MAP kinase, however, so far a change of Swiss 3T3 ®broblasts were synchronized by serum starvation followed by addition of serum for the time periods (in hours) indicated at the top and bottom. The onset of the S-phase was determined by incorporation of [ 3 H]thymidine (a) Polyadenylated RNA isolated from the cells at dierent time-points was analysed by Northern blotting using probes speci®c for A-myb (b), B-myb (c) or DNA-polymerase a (d) the activity of c-Myb in response to phosphorylation has not been clearly demonstrated. In addition, mitosis speci®c phosphorylations have been described for cMyb (LuÈ scher and Eisenman, 1992) . The role of these phosphorylations has not been addressed further. The cyclin-dependent regulatory mechanism described here is clearly dierent from the CKII and MAP kinase induced phosphorylation of c-Myb. It remains to be seen whether the cyclin-dependent phosphorylation represents only one aspect of the regulation of AMyb and whether additional mechanisms, involving other kinases, aect the activity of the protein.
A-Myb is a potential target for cyclin E/CDK2 and cyclin A/CDK2
Our work identi®es A-Myb as a potential target for cyclin A/CDK2 and cyclin E/CDK2. Although cyclins A and E have been studied in detail, very little is known about their physiological targets (for review see: Nigg, 1995) . Cyclin E plays a major role during the G 1 / S-phase transition and its overexpression results in shortening of the G 1 phase Ko et al., 1992; Ohtsubo and Roberts, 1993; Resnitzky et al., 1994; Wimmel et al., 1994) . Cyclin E allegedly is involved in the phosphorylation of the retinoblastoma protein during the late G 1 phase (Hinds et al., 1992; Hatakeyama et al., 1994) . Furthermore, Cyclin E/ CDK2 together with p107, a relative of the retinoblastoma protein, is associated with certain members of the E2F-DP transcription factor family Shirodkar et al., 1992) . However, the role of cyclin E in these complexes has not been clari®ed and it is not known whether E2F is phosphorylated by cyclin E/CDK2. Cyclin A is required during the Sphase of the cell cycle (Girard et al., 1991; Pagano et al., 1992; Sherr, 1993; Draetta, 1994) . Cyclin A/CDK2 is also associated with E2F and has been shown to phosphorylate E2F, thereby causing inhibition of E2F DNA-binding activity during S-phase Shirodkar et al., 1992; Dynlacht et al., 1994; Krek et al., 1994 Krek et al., , 1995 Xu et al., 1994) . We have shown here that A-Myb, unlike E2F, is activated by cyclin A/CDK2 kinase; together with the recent observation that the transactivation potential of BMyb is also increased by cyclin A/CDK2 (Sala et al., 1997; Ziebold et al., 1997) our results thus provide strong evidence for a stimulatory role of cyclin A/ CDK2 during S-phase. Further work, such as the identi®cation of the genes whose expression is aected by A-Myb, will therefore not only provide insight into the function of A-Myb but may also shed light onto the role of cyclins E and A at the G 1 /S-transition and during the S-phase.
Materials and methods
Cell cycle analysis
Swiss 3T3 cells were synchronized by serum starvation as described (Frost et al., 1995) . To measure DNA-synthesis, cells were incubated for 15 min with 5 mCi/ml of [ 3 H]thymidine (Amersham, 83 Ci/mmol) at dierent times after addition of serum. Aliquots of the labeled cells were precipitated with 10% trichloroacetic acid and counted in a liquid scintillation counter. Preparation of polyadenylated RNA, Northern blotting and detection of mouse A-myb and B-myb mRNAs were performed as described (Trauth et al., 1994; Sitzmann et al., 1996) . To visualize DNA polymerase a mRNA a 1.2 kb mouse DNA polymerase a cDNA fragment (kindly provided by R Watson) corresponding to nucleotides 3019 ± 4207 of the human cDNA was used as probe.
Eucaryotic expression vectors
Expression vectors for human cyclins A (pRc/cycA), cyclin D1 (pRc/cycD1) and cyclin E (pRc/cycE) were obtained from R Weinberg (Hinds et al., 1992 ). An expression vector for a dominant-negative mutant of human CDK2 (pCMV-cdk2dn) was obtained from E Harlow ( Van den Heuvel and Harlow, 1993) . The expression vector for cMyb was obtained by cloning the complete coding region of mouse c-Myb into pCDNA3 (Invitrogen). An expression vector for full-length mouse A-Myb (pCDNA3mAmyb) has been described (Trauth et al., 1994) . pCMVmAmybDBamHI is a derivative of this vector encoding an A-myb protein that is truncated at the C-terminus and consists of A-Myb aminoacids 1 ± 368. pCMVmAmybDBamHI was deleting all A-Myb coding sequences 3' of a unique BamHI site present in the A-Myb coding region. pCMVGal4mAmyb encodes a fusion protein of the Gal4 DNA-binding domain (aminoacids 1 ± 147) and full length mouse A-Myb. pCMVGal4mAmybDBamHI and pCMVGal4mAmybDMunI are derivatives of pCMVGal4mAmyb and encode fusion proteins of the Gal4 DNA binding domain and A-Myb aminoacids 1 ± 368 and 291 ± 754, respectively.
In vitro kinase reactions
An expression vector encoding a GST/A-Myb fusion protein was obtained by cloning a Bg1II/XbaI restriction fragment of mouse A-Myb (encoding A-Myb aminoacids 546 to 754) into pGex4T-1 (Pharmacia). A GST/B-Myb expression vector was obtained by cloning a PCR-ampli®ed fragment of mouse B-Myb (corresponding to B-Myb aminoacids 534 to 704) into pGex5X-3. In vitro kinase assays were performed according to Draetta et al. (1987) . Brie¯y, cyclin A/CDK2 complexes were precipitated from extracts of untransfected QT6 cells or of QT6 cells transfected with 10 mg each (per 10 cm tissue culture dish) of expression vectors for cyclin A (pRc/CycA) and CDK2 (pCMV-CDK2). Immunoprecipitation was performed as described , using a CDK2-speci®c antiserum (M2, St Cruz). Immunoprecipitates were collected on 20 ml protein A sepharose (Pharmacia) per 10 cm tissue culture dish. GST-proteins were expressed using standard methods. To purify GST-proteins 1 ml crude bacterial extracts were incubated with 20 ml of GSTsepharose (Pharmacia) followed by washing the sepharose beads three times with PBS (supplemented with 1 mM PMSF). Aliquots of the GST-beads were analysed by Western blotting using mouse A-Myb speci®c antiserum (Trauth et al., 1994) . Sepharose beads containing the active kinase complex (10 ml) and GST protein (10 ml, approximately 1 to 2 mg protein) were mixed, washed once with 1 ml kinase buer (50 mM MOPS, pH 7.2; 10 mM MgCl 2 ; 1 mM DTE; 0.05% NP40) and suspended in 5 ml of kinase buer. After preincubation for 5 min at room temperature 5 ml of ATP-mix (containing 40 mM unlabeled ATP and 2 mCi g[ 32 P]-ATP (5000 Ci/mmol; Amersham) were added. After incubation for 15 min at 308C the reaction was stopped by adding an equal volume of 26SDS-sample buer. The radiolabeled proteins were then analysed by SDS ± PAGE and autoradiography. Transfection p3xATk-Luc contains three copies of a myb binding site from the mim-1 gene upstream of the HSV thymidine kinase promoter and the luciferase gene (Ness et al., 1989) . pG5E4-38Luc contains ®ve Gal4-binding sites upstream of the adenovirus E4 promoter (positions 738 to +38) and the luciferase gene. CMBb (Clontech) contains a CMV promoter-driven b-galactosidase gene. Transfections were carried out as described (Burk et al., 1993) using the quail ®broblast cell line QT6 (Moscovici et al., 1977) . The amounts of DNA used for transfection are indicated in the ®gure legends and correspond to a 10 cm tissue culture plate. Cell extracts were prepared by suspending the cells in 200 ml per plate of lysis buer (50 mM HEPES, pH 7.5; 250 mM KCl; 0.1% NP40; 10% glycerol; 1 mM DTE) and keeping them for 20 min on ice. Lysates were clari®ed by centrifugation in a microfuge and used for luciferase and bgalactosidase assays as described (Burk et al., 1993) . For protein analysis lysates were prepared in the presence of 4 mM NaF; 0.5 mM sodium vanadate and 10 mM PMSF. Mouse A-Myb and c-Myb were visualized by Western blotting, using the monoclonal antibody 5E11 (Sleeman, 1993) . Gal4/A-Myb fusion proteins were detected by using the Gal4-speci®c monoclonal antibody (RK5C1, St Cruz Biotechnology).
In vivo labeling and phosphatase treatment
Transfected cells were labeled with [
35 S]-methionine by incubating them with [
35 S]-methionine (Amersham, 4800 Ci/mmol) in methionine-free medium at 33 mCi/ml for 2 h. Before labeling, cells were preincubated in methionine-free medium for 30 min. For immunoprecipitation (all steps on ice), cells were washed with cold tissue culture medium lacking serum but supplemented with 4 mM NaF; 0.5 mM sodium vanadate. Subsequently, the cells were lysed in 1 ml lysis buer (10 mM Tris-HCl, pH 7.8; 140 mM NaCl; 1% Triton X-100; 0.1% SDS; 1% sodium desoxycholate; 4 mM NaF; 0.5 mM sodium vanadate; 10 mM PMSF) per 10 cm tissue culture plate.
The lysate was sheared with a syringe and clari®ed for 10 min in a microfuge. Aliquots of the lysate were immunoprecipitated with mouse A-Myb speci®c antiserum (Trauth et al., 1994) . Precipitates were collected using protein-A sepharose (Pharmacia) and washed four times with lysis buer. Phosphatase treatment of the immunoprecipitate was performed as described (Chen and Blenis, 1990) . Brie¯y, the immunoprecipitate was washed once with phosphatase buer (20 mM MES, pH 6.0; 20 mM KCl; 1 mM DTE; 1 mM MgCl 2 ; 1% aprotinin; 5 mg/ml leupeptin; 5 mg/ml pepstatin), suspended in 30 ml of the same buer and treated for 30 min at 308C with 0.35 U potato acid phosphatase (PAP, Boehringer). After 15 min further 0.35 U PAP were added to the reaction mixture. Control samples were treated either with phosphatase buer alone, with heat-inactivated PAP or with PAP in the presence of a cocktail of phosphatase inhibitors (100 mM sodium vanadate; 20 mM b-glycerol phosphate; 4 mM NaF). Finally, the samples were washed with phosphatase buer and analysed by SDS ± PAGE and autoradiography. For phosphate labeling cells were preincubated in phosphatefree medium (DMEM, ICN) containing 5% dialyzed fetal calf serum for 30 min and then incubated for 5 h with 400 mCi/ml [ 32 P]orthophosphate (Amersham, HCl-and carrier-free) in the same medium. Cells were lysed as described above, lysates were clari®ed by centrifugation in a microfuge and immunoprecipitated using mouse A-Myb speci®c antiserum. Finally, immunoprecipitates were analysed by SDS ± PAGE and autoradiography.
